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Abstract
Nanomedicine utilizes the remarkable properties of nanomaterials for the diagnosis, treatment, and 
prevention of disease. Many of these nanomaterials have been shown to have robust antioxidative 
properties, potentially functioning as strong scavengers of reactive oxygen species. Conversely, 
several nanomaterials have also been shown to promote the generation of reactive oxygen species, 
which may precipitate the onset of oxidative stress, a state that is thought to contribute to the 
development of a variety of adverse conditions. As such, the impacts of NMs on biological entities 
are often associated with and influenced by their specific redox properties.
In this review, we overview several classes of nanomaterials that have been or projected to be used 
across a wide range of biomedical applications, with discussion focusing on their unique redox 
properties. Amongst the nanomaterials examined include iron, cerium, and titanium metal oxide 
nanoparticles, gold, silver, and selenium nanoparticles, and various nanoscale carbon allotropes 
such as graphene, carbon nanotubes, fullerenes, and their derivatives/variations. Principal topics of 
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discussion include the chemical mechanisms by which the nanomaterials directly interact with 
biological entities and the biological cascades that are thus indirectly impacted. Selected case 
studies highlighting the redox properties of nanomaterials and how they affect biological responses 
are used to exemplify the biologically-relevant redox mechanisms for each of the described 
nanomaterials.
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Introduction
Nanomedicine, the medical application of nanotechnology, harnesses the properties of 
nanomaterials (NMs) for biomedical applications, including diagnostic assays, therapeutic 
delivery systems, and tissue engineering.1–4 While NMs are renowned and utilized due to 
their remarkable properties, such as their optical, thermal, or magnetic properties, their 
redox properties are also pertinent to their safe and effective use in the biomedical sector.5 
One such biomedical application where NMs have been shown to have much promise is in 
antioxidant activity, specifically in the scavenging of reactive oxygen species (ROS).6
ROS are oxygenated redox active species that are produced in the body as normal 
byproducts of metabolic processes or accumulated from the environment.7–9 Examples of 
ROS include hydrogen peroxide (H2O2), superoxide (O2•−), singlet oxygen (1O2), and the 
highly reactive hydroxyl radical (•OH).10 While ROS are widely used throughout the body 
as signaling molecules,11 they can also damage biological entities (e.g. proteins, lipids, 
DNA).7 Elevated levels of ROS and oxidative damage can result in oxidative stress, a state 
that is thought to contribute to the development of a variety of adverse human conditions, 
including cancer, neurodegenerative diseases, and cardiovascular diseases.12–14 To 
counteract the often adverse effects of oxidative stress, several antioxidative mechanisms 
exist which serve to balance ROS levels.15 Amongst these antioxidants are the superoxide 
dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) families of 
enzymes.9, 10, 15 Whereas SOD typically catalyzes the dismutation of O2•− into H2O2, CAT 
and GPx catalyze the decomposition of H2O2 into water.9, 10 In the case of GPx, glutathione 
(GSH), a selenium-containing molecule, is oxidized to glutathione disulfide (GSSG). 
Antioxidant NMs have been shown to scavenge ROS via mechanisms analogous to that of 
the body’s natural antioxidative mechanisms and are hence, sometimes described as having 
enzyme-mimetic activities.16, 17
The redox properties of NMs can also be pro-oxidative, leading to the generation of ROS. 
This excessive generation would presumably lead to the disruption of the aforementioned 
antioxidant mechanisms, inducing the progression of oxidative stress and the previously 
described adverse effects associated with it.18, 19 However, these pro-oxidative redox 
properties can also be harnessed for useful applications. One such example is the treatment 
of cancer (one such disease associated with oxidative stress) either through the direct 
production of ROS or via photodynamic therapy (PDT). PDT utilizes a photosensitizing (PS) 
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agent that has been localized to a tumor and the activation of that agent via light.20 
Specifically, the localized PS is excited by laser light of a suitable wavelength to form a 
singlet excited state photosensitizer (PS*).21 The PS* then undergoes an intersystem 
crossing to form a triplet excited state (PS**) which can then either 1) induce electron 
transfer to the surrounding environment and generate ROS (typically free radicals such 
as •OH or O2•−), denoted Type I or; 2) undergo an energy transfer process with ground 
state 3O2 to produce singlet 1O2, denoted Type II.21 Regardless of the mechanism of 
generation, these NM-generated ROS could then proceed to damage and destroy vital tumor 
biomolecules, functioning as cytotoxic agents if applied specifically to cancerous cells.
In this review, we overview several classes of NMs that have been or projected to be used 
across a wide range of biomedical applications, with discussion focusing on their unique 
redox properties and their effects on biological systems. The NMs examined include iron, 
cerium, and titanium metal oxide nanoparticles (NPs), gold, silver, and selenium 
nanoparticles, and various nanoscale carbon allotropes such as graphene, carbon nanotubes 
(CNTs), fullerenes, and their derivatives/variations. These are amongst the most common 
NMs being researched for applications in nanomedicine. Principal topics of discussion 
include the chemical mechanisms by which these NMs directly interact with biological 
entities and the biological cascades that are thus indirectly impacted. Selected case studies 
highlighting the redox properties of nanomaterials and how they induce biological responses 
are used to exemplify the biologically-relevant redox mechanisms for each of the described 
nanomaterials. Each case study is described and discussed in detail, accompanied by 
commentary of the work’s significance towards advancing our understanding of nano-bio 
redox mechanisms and their influence on nanomedicine modalities.
Iron Oxide Nanoparticles
Iron oxide NPs (IONs) are amongst the most heavily researched and potentially versatile 
NMs for biomedical applications, which range from magnetic resonance imaging (MRI) and 
cell tracking to targeted therapeutics and tissue engineering.22, 23 Most of these applications 
exploit the IONs’ interesting property of superparamagnetism, wherein the particles exhibit 
magnetism only in the presence of an external magnetic field, which ceases when this 
external field is removed.24, 25 As such, it is possible to use superparamagnetic IONs 
(SPIONs) to generate heat when an alternating magnetic field is applied; alternatively, they 
may be directed to specific tissues/organs using an external magnetic field.26, 27 Relative to 
other common paramagnetic elements/complexes (e.g., Cobalt, Nickel, Gadolinium-
complexes), SPIONs are also thought to have reduced toxicity and increased 
biocompatibility;28, 29 combined with their superparamagnetism and colloidal stability, they 
are quite appealing for applications in nanomedicine.30, 31
While most of these biomedical applications utilize the SPIONs’ magnetic properties, their 
other physicochemical properties (e.g., size, surface chemistry, surface coating) have greater 
influence on their interactions with biological entities (e.g., proteins, cells, tissues).31, 32 
Highlighted amongst these properties is the redox chemistry of SPIONs, which heavily 
depends on the particles’ chemical composition. SPIONs primarily exist in the forms 
magnetite (Fe3O4) or maghemite (γ-Fe2O3),24, 25 both of which form inverse spinel 
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structures, where the oxygen anions are arranged as a face-centered cubic and the iron 
cations occupy interstitial tetrahedral and octahedral sites.33 Given the structural similarities, 
the most apparent difference between the two forms are that magnetite contains both Fe2+ 
and Fe3+ ions, while the iron in maghemite is almost entirely in the Fe3+ state.33 Systemic 
quantities of the two Fe oxidation states are important due to their role in catalyzing a series 
of ROS generating reactions, specifically the Fenton and Haber-Weiss reactions:34, 35
(1)
(2)
(3)
(4)
As shown, both Fe states can lead to ROS formation (•OH, •OOH, O2•−), which can induce 
oxidative stress through various mechanisms described earlier. SPIONs have been shown to 
cause oxidative stress across many studies, including promotion of oxidative DNA damage 
in human lymphoblasts,36 disruption of lysosomal and mitochondrial function in rat 
cardiomyocytes,37 and apoptosis of human macrophage mediated by overactivation of the c-
Jun N-terminal kinase (JNK) signaling cascade.38
While SPIONs have been shown to have toxic effects on biological systems, a key factor in 
the ability of SPIONs to cause oxidative damage is their ability to liberate free Fe. Coating 
the SPIONS with biocompatible compounds (e.g., lipids, polyethylene glycol (PEG), 
dextran) not only increases their colloidal stability and minimizes their nonspecific 
interactions with biomolecules,25, 26 but also helps to reduce their degradation into free Fe, 
which produces more ROS relative to intact SPIONs.39 While much research has been done 
to characterize the physicochemical properties of SPIONs with respect to the colloidal 
coating, their interactions with biological systems are difficult to ascertain since the nature 
of the interaction depends not just on the properties of the SPIONs, but also on the 
biological system itself.28, 32, 38, 40–42 For example, PEGylated SPIONs have been found to 
increase DNA damage in mice lung tissue at a much lower degree as compared to non-
PEGlyated SPIONs; in addition, negatively charged PEGlyated SPIONs were found to 
induce slightly more DNA damage than their positively charged counterparts.40 However, 
another study of multiple human cell lines (HCM, BE-2-C, and 293T) found that the 
positively charged SPIONs led to lower cell viability relative to negatively charged 
SPIONs.32 As such, the effects of SPION redox mechanisms will vary per the specific 
parameters of the overall system.
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Previous studies had shown that SPIONs could catalyze oxidation of peroxidase substrates 
in acidic solutions in the presence of H2O2 through reaction (1); this SPION-based reaction 
was termed a peroxidase-like activity.43 Likewise, under more neutral pH conditions, 
SPIONs lose their peroxidase-like activity and instead catalyze the disproportionation of 
H2O2 into H2O and O2; this reactivity was termed a catalase-like activity.44 The catalase-like 
mechanism is proposed to occur through reactions (2) and (3) in combination with reaction 
(5) below:45
(5)
Based on these observations, Chen et al.45 investigated the interaction of SPIONs with H2O2 
in human glioblastoma cells, with the goal of devising a scheme to diminish the cytotoxic 
effects of the SPIONs. Using Fe3O4 and Fe2O3 SPIONs, the authors found that both types of 
particles were readily taken up by the cells after 12 h of exposure. Most of the SPIONs 
localized to the lysosomes. Viability assays showed that the Fe2O3 particles had little toxic 
effect on the cells, which were more than 85 % viable across all tested concentrations. 
Conversely, the Fe3O4 particles showed dose-dependent toxicity. These observations were 
supported by electron spin resonance (ESR) spectroscopy measurements conducted at pH 
4.8 and pH 7.4 to mimic the environments of lysosome and cytosol respectively.45 The ESR 
results showed that both types of SPIONs produced •OH at pH 4.8, while the Fe3O4 particles 
produce more radicals (increased peroxidase-like activity) than their Fe2O3 counterparts 
(recall that Fe3O4 contains Fe2+ while Fe2O3 is fully comprised of Fe3+). Interestingly, •OH 
production was not observed at pH 7.4 for either type of SPION, which suggested a catalase-
like activity. Under these conditions, it was believed that the SPIONs effectively functioned 
as a ROS scavenger (antioxidant activity) rather than a ROS producer (pro-oxidant activity). 
As such, along with the authors’ findings that Fe3O4 particles are more toxic than Fe2O3 
particles, the idea that SPIONs could be used to protect cells from oxidative stress under 
specific conditions was an important outcome of the study.
Building off of this, Huang et al.46 sought to harness the toxic effects of SPIONs to improve 
the therapeutic effect of β-lapachone (β-lap), an anticancer drug which operates by inducing 
necrosis via poly(ADP-ribose) polymerase 1 (PARP1) hyperactivation. This mechanism 
operates through elevated levels of H2O2 and O2•−. Fe3O4 SPIONs were synthesized and 
then incorporated into micelles comprised of poly(ethyleneglycol)-b-poly(2-(2-
diisopropylamino) ethyl methacrylate (PEG-b-PDPA), a pH-sensitive amphiphilic 
copolymer. To test for pH-sensitive release of the SPIONs, Fe concentrations in buffers at 
pH 7.4, 6.2, and 5.0 were measured by atomic absorption spectrometry after 72 h. At pH 7.4, 
Fe ions were not observed, while Fe was found at the lower pH values in increasing 
quantities. The mechanism of release was attributed to the protonation of the PDPA 
segments of the polymer, leading to micelle dissociation and release of SPIONs, which 
could then be degraded to free Fe ions at the lower pH. The authors then treated lung 
carcinoma cells with the SPION-micelles, both with and without β-lap (which was also 
tested without SPIONs) for 48 h. After 4 h of incubation, >80 % of the SPION-micelles 
were localized in the endosomes (pH 5.5 to 6.3) and lysosomes (pH 5.0 to 5.5), although Fe 
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ion release was found to take longer (only 40 % of the total Fe ions were released at pH 5.0 
after 48 h in the initial pH sensitivity test). A fluorescence assay indicated cells treated with 
SPION-micelles only showed no effect, while cells treated with β-lap only produced very 
little fluorescent signal; both findings suggest a limited production of ROS under their 
respective conditions. However, the cells treated with both β-lap and SPION-micelles had 
over 10-fold higher fluorescence intensity, suggesting a more than 10-fold increase in ROS 
levels. The massive increase in ROS production from the synergistic treatments was 
corroborated by long-term cell survival assays. Under experimental conditions, the cell 
survival rate fell from 72 % to 10 % when SPION-micelles were added to the β-lap 
treatment. When compared in combination with the previously discussed properties of 
SPIONs, these SPION-micelles show promise for use in theranostic nanomedicine against 
various cancer types.
However, heightened ROS levels as promoted by SPIONs are often detrimental to biological 
systems and impact their use in most of their designed applications. A recent study by 
Pongrac et al.47 monitored several oxidative stress endpoints in mouse neural stem cells 
(NSCs) to investigate the impact of different surface functionalizations (uncoated, D-
mannose-coated, and poly-L-lysine-coated) on SPION toxicity. Due to their ability to 
differentiate into many types of specialized cells, stem cells are the focus of much research 
attention for their use in regenerative medicine therapies.48 Cell tracking via SPION-based 
MRI is one of the most promising methods for monitoring stem cell migration and 
differentiation, two essential processes in therapeutic stem cell treatment.49 While viability 
assays did not show significant reductions in NSC viabilities across the SPION 
concentration levels examined, levels of glutathione (GSH) were greatly depleted. The 
authors also found significant decreases in superoxide dismutase (SOD) activity, with 
corresponding increases in glutathione peroxidase (GPx) activity; these observations 
indicated that the NSCs were under significant oxidative stress upon SPION treatment. 
Assessments of mitochondrial membrane potential (MMP) and cell membrane potential 
(CMP) changes, along with DNA damage measurements, substantiated the results of earlier 
experiments for the SPION-exposed NSCs, where severe detrimental effects of excessive 
ROS were seen for all SPIONs investigated. Interestingly, surface coating appeared to have 
little impact on the toxicity of the SPIONs, as significant differences between toxicity end 
points were not observed as a function of coating. Also of note were the authors’ discussions 
regarding the possibility that underlying cellular functions could still be impaired despite 
“rough” toxicity end-points measurements (e.g., cellular viability, ROS levels) approaching 
their limit of detection.47
Umashankar et al.50 also studied the effects of SPIONs on NSCs; specifically, the influence 
of Molday ION Rhodamine B (MIRB) (a commercially available SPION used for cell 
labelling, tracking, and MRI) on the survival and regenerative capacity of rat NSCs both in 
vitro and in vivo. While the NSCs could be detected when labeled at both doses (20 μg and 
50 μg) of MIRB, the higher dose was found to increase MRI contrast signal, which seems to 
be an unsurprising result. The 50-μg dose significantly compromised the viability and 
proliferation of the NSCs in vitro, yet the 20-μg dose did not appear to affect these two 
cytotoxicity endpoints when compared to the untreated control NSCs. The ability of the 
MIRB-labeled NSCs to generate a differentiated cell type and morphology was assessed. 
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The 50-μg dosed NSCs featured substantial reductions in differentiated cells with the 
differentiated cells also having altered morphological characteristics. Curiously, despite no 
significant impact on the generation of differentiated cells, the 20-μg dosed NSCs exhibited 
differences in morphology compared to the control. In practice, these morphology 
alterations could have massive ramifications for in vitro production and in vivo grafting of 
SPION-labeled NSCs.50 In vivo measurements of contrast signal, NSC graft size (a measure 
of NSC viability), and proliferation all generally agreed with the in vitro results: the 50-μg 
dosed group had more adverse outcomes than the 20-μg dosed group. In all circumstances, 
increased ROS production resulting from the presence of SPION was suggested to be the 
major contributor to the observed differences between the control and MIRB-treated NSCs.
While SPIONs are promising for several applications in the field of nanomedicine, these 
studies highlight their propensity to produce toxic amounts of ROS. While this toxicity can 
be utilized for cancer treatments, other applications will require greater control of toxicity 
mechanisms to enable translation of SPIONs into the clinical setting. As described earlier, 
controlling the chemical nature of the SPION coating (e.g., identity, charge) is just one 
approach to mitigate their toxicity. Other strategies under investigation include encapsulating 
SPIONs within liposomes, SPION surface passivation with shielding silica shells, and 
pretreatments to enhance antioxidant levels prior to SPION introduction.51
Cerium Oxide Nanoparticles
Cerium oxide NPs (CNPs) are widely used in industry as chemical mechanical polishing 
agents, in anticorrosion coatings, and as an additive in diesel fuel.52 However, the potential 
benefits of CNPs for medical applications have only recently gained interest due to several 
studies that showed antioxidant properties in cell models.53–55 These antioxidant properties 
result from the coexistence of Ce3+ and Ce4+ states on the surface of the particles,56–58 
which contribute to the high chemical reactivity of CNPs. While Ce4+ is the more stable 
oxidation state, oxygen release routinely occurs, forming Ce3+ along with an oxygen 
vacancy to maintain the positive charge.59 While this redox state exists in the bulk form, the 
greater surface area to volume ratio associated with NPs means that more reactive species 
are located at the surface of CNPs, on a mass basis. This allows CNPs to act as both a source 
and a sink for oxygen. Additionally, CNPs exhibit activity similar to biological enzymes 
such as phosphatases,60, 61 oxidases,62, 63 peroxidases,64 and ATPases,65 which is partly the 
result of their Ce3+ and Ce4+ surface states. The redox properties (and hence, biological 
redox activity) of CNPs are highly dependent upon the synthesis method utilized, the 
implications of which have been thoroughly discussed in recent literature.66–68
CNPs are thought to have particular promise for the treatment of neurodegenerative diseases, 
such as Alzheimer’s syndrome (ALZ) and multiple sclerosis (MS).9 ALZ is thought to be 
triggered, in part, by increased production of ROS in the mitochondria, which can lead to 
neuronal cell death.69 Using CNPs designed to localize to the mitochondria, Kwon and Cha 
et al.70 demonstrated that transgenic ALZ mice have increased neuronal cell density 
compared to CNP-untreated mice. Based on additional experiments, they found that ROS-
induced brain inflammation can lead to neuronal loss, but that CNPs reduce this ROS 
accumulation. From this, they surmise that CNPs reduce inflammation by scavenging ROS, 
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which thereby reduces neuronal cell death. It is worth noting that these CNPs had a 
triphenylphosphonium coating, giving them a positive charge which allowed them to 
accumulate in the mitochondria. CNPs without this coating were distributed randomly in 
human neuroblastoma cells. Similarly, a mouse MS model treated with CNPs exhibited 
significantly improved motor functions and reduced brain ROS concentrations compared to 
control mice.71 In this study, the CNPs were coated with citrate and 
ethylenediaminetetraacetic acid (EDTA), which allowed them to maintain stability and 
osmolality at physiological pH and resist biofouling. The authors argued that this 
preparation technique is why, unlike other studies, their CNPs did not accumulate in the liver 
and spleen, but remained in circulation longer.
The ability of CNPs to reduce inflammation may have other medical uses as well. Davan et 
al.72 found that CNPs applied to wounds in rats reduced healing time and scarring by 
increasing collagen production at the wound site. The researchers demonstrated this by 
surgically removing dorsal skin (2 cm in diameter) from rats and applying a daily mixture of 
CNPs in paraffin to the wounds. Wound diameter was measured daily and wound tensile 
strength was measured after 12 d. The researchers found that rats receiving an application of 
2 % CNPs had decreased wound sizes after 1 d which continued until 12 d, compared to rats 
that were untreated, treated with 1 % CNPs, or treated with povidone iodine, a common 
over-the-counter antiseptic. Wound tissue was removed after the 12 d treatment and tested 
for tensile strength and collagen-marker (hydroxyproline) content. Excised wound tissue 
from rats treated with 2 % CNPs had more than double the tensile strength and 
hydroxyproline content of non-treated rats and approximately 40 % greater tensile strength 
and hydroxyproline content compared to rats treated with povidone iodine. The researchers 
attribute the wound healing attributes of CNPs to their ROS scavenging ability, which 
follows from their dual oxidation states.72 Similarly, Chigurupati et al.73 found that CNPs 
aid in wound healing in mice. They began by examining the impact of CNPs on fibroblast 
and keratinocyte cell proliferation in vitro and found that cell proliferation was significantly 
increased when incubated with 1 μmol L−1 or 10 μmol L−1 CNPs compared to controls. 
They then tested this in vivo by excising dorsal tissue (4 mm in diameter) in mice and 
applying 10 μmol L−1 CNPs topically to the wounds daily for 13 d. CNP treated mice had 
significantly smaller wounds after 1 d and were almost completely healed by 13 d compared 
to control animals that still had an average wound size of approximately 1.2 mm in 
diameter.73 Wound healing was examined by immunostaining tissue sections and examining 
smooth muscle actin (SMA). SMA was significantly higher in the mice treated with CNPs 
compared to the control animals at 5 d, 8 d, and 13 d post injury. This suggests that skin cell 
differentiation into activated myofibroblasts was increased by CNPs; myofibroblasts are 
beneficial to the wound healing process. Additionally, increased blood vessel density and 
almost triple the number of leukocytes were found in wound tissue of mice treated with 
CNPs compared to control, indicating better tissue oxygenation, better debris clearing, and 
enhanced anti-infection host-control of tissues treated with CNPs.73
CNPs have also been assessed for the treatment of cancers due to their antioxidant 
properties. Cancer cells typically have high levels of ROS, which act in several ways to help 
maintain the cancerous phenotype, though, for example, signaling and promoting 
mutations.74, 75 Alili et al.76 found that polymer coated CNPs were not toxic to stromal cells 
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but showed dose dependent toxicity to cultured human melanoma cells in vitro. The 
researchers then used a mouse model to test the effects of CNPs on tumor growth. Mice 
were implanted with melanoma cells and injected with either a mock treatment or with 
CNPs at 0.1 mg kg−1 every other day for 30 d. Mice receiving the CNP treatment had 
significantly smaller tumors compared to the mock treatment group. Cell viability assays 
indicated no impact on normal cells, but a 45 % decrease in viability of melanoma cells after 
96 h. CNPs were shown to decrease the invasive capacity of tumor cells by 70 %.76 
Decrease in cell viability and tumor growth seems to be related to pro-oxidant effects in 
tumor cells with no such effects observed in normal cells. This pro-oxidant effect seems to 
be related to the higher lactate and H+ production in cancerous cells compared to non-
cancerous cells. When additional H+ is present, Ce3+ reacts with H+ and O2•− to produce 
Ce4+ and H2O2 according to the following reaction (6):
(6)
The researchers investigated this effect by examining the influence of CNPs on apoptosis in 
fibroblast cells.77 They found that by incubating fibroblast cells in 150 μmol L−1 CNPs for 
24 h and then exposing them to H2O2, cytochrome c release from mitochondria was 
drastically reduced compared to non-CNP incubated cells. Additionally, by incubating 
fibroblasts with CNPs for 5 d, cell proliferation was increased by 180 % compared to control 
cells. The enhanced growth rate was comparable and slightly higher than that found from 
other antioxidants such as N-acetyl cysteine (NAC), sodium selenite, or Trolox.77
While positive impacts of CNPs seem promising for medical treatments, Yokel et al.78 warn 
of the toxicity associated with CNPs and their potential biopersistence in humans. Rats 
intravenously injected with CNPs at concentrations of 50 mg kg−1, 250 mg kg−1, or 750 mg 
kg−1 showed a dose-dependent increase in Ce concentrations post injection. The highest Ce 
concentrations were found in the spleen, with decreasing concentrations found in in the liver, 
blood, and the brain.79 While the brain showed the lowest concentration of cerium, 
significantly increased levels of protein bound 4-hydroxy-2-nonenal (HNE) were detected in 
the hippocampus 20 h post injection, indicating oxidative stress and potential oxidative 
damage. HNE is highly reactive and can bind proteins to cause functional changes. However, 
the authors point out that the CNPs were purchased from a commercial vendor and had an 
unknown surface coating. Any coating on the CNPs may alter their biocompatibility, 
biodistribution, and biopersistence. Similarly, mice injected with CNPs weekly for 2 to 5 
weeks at 0.5 mg kg−1 per dose, a much lower dose than the previous study discussed, had 
the highest Ce concentrations in the spleen, followed next by the liver, lungs, and kidneys.80 
No toxicity was observed in these mice, instead, CNPs acted as an antioxidant in mice 
treated with CCl4 to induce liver toxicity via oxidative damage. CNPs worked as well as, if 
not better than, NAC, a commonly used antioxidant that reduces oxidative stress. However, 
mice cleared very little of the Ce injected, suggesting biopersistence of these particles. 
Interestingly, mice given CNPs orally excreted 95 % of them within 24 h. CNPs used by 
Hirst et al.80 were coated with carboxyfluorescein, most likely different from the unknown 
coating used by Yokel et al.79
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The unique redox surface chemistry of CNPs, which gives them both anti- and pro-oxidant 
potential, make these NPs attractive for the medical field. Studies suggest that CNP 
treatment can influence wound healing, reduce neuronal cell death, and arrest the growth of 
tumor cells in mice through the amplification of ROS. These results, combined with their 
low toxicity towards wildtype cells, make CNPs a promising modality for nanomedicine 
applications.
Titanium Oxide Nanomaterials
Titanium dioxide (TiO2) and its nanoconstituents (TiO2NMs) have garnered interest towards 
employment in a plethora of applications in biomedicine. This material has been shown to 
be an excellent candidate material for incorporation into dentistry (as dental implants) and 
orthopedics due to factors such as high corrosion and wear resistance, high strength, 
durability, low density, and especially, biocompatibility.81–85 In fact, the biocompatibility 
and bioinertness of this material has been associated with the formation of native oxide 
layer(s) on the TiO2 surface when the material comes into contact with air.86
TiO2 NMs show much promise as a PS for PDT cancer treatment applications due to their 
hydrophilicity and ability to generate electron-hole pairs when exposed to ultraviolet (UV) 
radiation. These electron-hole pairs, generated after the introduction of TiO2 into living 
tissues or cells, can react with surrounding oxygen to form various ROS such as H2O2, •OH, 
or O2•−.87, 88 The effective production of ROS by TiO2NPs is the main contributing factor in 
its successful use as cytotoxic reagents in human cervical adenocarcinoma,89 
hepatocarcinoma,90 non-small cell lung cancer,91 breast cancer,92 and leukemia93 cell lines. 
In an early study, Cai et al.89 demonstrated the ROS generating capability (as well as the 
potential for tumor tissue penetration) of TiO2NPs as they found that 10 min UV irradiation 
of TiO2 particles at 50 μg mL−1 was sufficient for complete HeLa cell death. Exposure of 
TiO2 treated cells to a 500-W mercury lamp resulted in a dramatic decrease in tumor cell 
survival (an 80 % reduction in cell survival was found after 5 min of irradiation, while 10 
min irradiation resulted in 100 % cell death). Additionally, tumor growth was suppressed in 
TiO2 treated cells for up to 30 d. Cytotoxic effects were attributed to the generation of ROS 
products such as •OH and H2O2 on the TiO2 surface. Later, TiO2 nanofibers were found to 
induce not only significant oxidative stress-mediated cytotoxicity at low doses, but also 
apoptosis in HeLa cells.94 TiO2NPs induced the formation of apoptotic features in A549 
cells.90 In the aforementioned study, during comparison of cell morphologies, control cells 
were found to be large, round, and contained dense microvilli with minor surface 
protrusions. In contrast, cells exposed to TiO2NPs were flat with rough cell membrane and 
thinner microvilli; they contained larger and more numerous protrusions. A decrease in 
MMP was found for TiO2NP-exposed A549 cells. Meanwhile, results from the comet assay 
agreed with similar studies,95–98 and revealed the dose-dependent DNA damage induced by 
TiO2NPs. In each of these studies, the superphotocatalytic properties of TiO2 materials were 
employed to investigate and demonstrate anticancer effects.
Conventional drug delivery and administration is often hampered by limitations such as low 
drug efficacy, poor bioavailability, drug degradation, etc.;99 however, the photocatalytic 
properties of TiO2 and its nanoconstituents make them suitable candidates for single and 
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multi-drug delivery treatments.100 Yadav et al. evaluated the biocompatibility of multimodal 
methoxy PEG (mPEG) TiO2 nanocoral structures (TiO2NCs) for chemotherapeutic drug 
delivery.101 They assessed the efficiency of these drug loaded TiO2NCs for tunable drug 
release of doxorubicin (DOX, mPEG-DOX-TiO2NCs) in cancer chemotherapy, especially 
under UV light. In vitro toxicity and drug release studies were performed by exposing L929 
and MCF-7 (breast cancer cell line) cells to bare TiO2NCs and mPEG-DOX-TiO2NCs and 
the level of ROS production in MCF-7 cells was measured using the 5-(and-6)-
chloromethyl-2,7-dichloro-dihydrofluorescein diacetate-acetyl ester (H2DCFDA) assay. Due 
to the uniquely high-surface area of the TiO2NC architecture, drug loaded TiO2NCs acted as 
not only as efficient drug carriers, but also mediated cancer cell death under light activation. 
mPEG-TiO2NCs were proven to facilitate higher DOX uptake and delivery into cells, and 
enhanced targeting of cancers cells, thus activating apoptosis (evidenced by cell shrinkage, 
cell extensions, and an increase in the number of floating cells) through the generation of 
excess ROS under UV illumination. ROS generation was attributed to the electron-hole pairs 
created by TiO2NCs under UV illumination. MCF-7 cells exposed to UV, bare TiO2NCs, 
and mPEG- DOX-TiO2NCs and after 20 min of irradiation displayed 71 %, 51 %, and 16 % 
cell viability, respectively indicating the anticancer effect of mPEG-TiO2NCs due to the 
production of free radicals such as •OH and O2•−.
Although TiO2NPs have been shown to be bioinert, evidence on the cytotoxic effects of 
smaller-sized particles has been demonstrated in the form of pulmonary inflammation, 
emphysema, and epithelial cell apoptosis.102–104 Additionally, TiO2NP exposure in vitro has 
resulted in damage to lipid, protein, and DNA, as well as cytoplasmic membrane 
rupture.104–106 In most cases, cytotoxic effects were a result of increased ROS generation 
after exposure. Zhu et al.107 investigated the influence of oncongenic transformation and 
apoptotic signaling pathway on cellular responses to TiO2NP-exposure in isogenic wild-type 
and apoptosis-resistant (Bak−/−Bax−/−) cell lines. Two pairs of wildtype (untransformed) 
mouse embryonic fibroblasts and their isogenic counterparts (one pair of cells expressed all 
Bcl-2 proteins and another pair was deficient in expression of two key proapoptopic Bcl-2 
proteins) were exposed to increasing concentrations of TiO2NPs (type P25) for 24 h. After 
24 h, TiO2NPs entered cells via endocytosis and were visualized as clusters of TiO2NPs 
sequestered within vacuoles inside the cell. Some of the particles were localized to the 
cytoplasm (which could have been resultant of lysosomal membrane rupture). They 
observed a dose-dependent decrease in the viability of all four cell lines tested. They 
provided evidence that TiO2NPs preferentially induce tumor cell death through a lysosome-
mediated pathway, and noted that lysosomal membrane permeability and necrosis resulted 
from severe oxidative stress. When comparing responses for transformed and untransformed 
cells, they also found that transformed cells were more sensitive to TiO2NPs. They regarded 
this preferential killing of transformed cells by TiO2NPs as a potential area of exploitation 
for cancer therapy.
While toxic effects are not ideal in the field of nanotechnology, exploitation of the 
photocatalytic properties of TiO2 led to the demonstration of TiO2-mediated cytotoxicity in 
cancer research. Lagopati et al.92 investigated the feasibility of employing TiO2 as an 
anticancer agent in the presence of ultraviolet light. They hypothesized that crystallinity 
would impact oxidant generation, and therefore explored the effect of the particle crystal 
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phase of TiO2 dispersions using two breast epithelium cancer cell lines: MDA-MB-468 and 
MCF-7. A reduced cell viability of both cell lines was exhibited with both 100 % anatase 
TiO2NPs and TiO2 P25 (anatase-rutile mixture [75 %: 25 %]) at increasing exposure 
concentrations. This decrease in viability was compounded under UVA irradiation. 
Photoexcited 100 % anatase TiO2NPs induced greater apoptosis and DNA fragmentation. 
Overall, they found that the highly malignant MDA-MB-468 cells were more susceptible to 
UVA-activated TiO2NP and induced cell death as compared to MCF-7 cells, especially in 
the case of treatment with the 100 % anatase NPs. This cytotoxic effect agreed with the 
conclusions of Sayes et al.,105 who found that anatase phase TiO2NPs generated more ROS 
in human dermal fibroblasts or A549 cells. The mechanism of TiO2NP cytotoxicity involved 
an increase in Bax-expression (one of the proteins integral in the cell apoptosis pathway) 
which was a novel finding about the exposure effects of pure anatase TiO2 versus anatase-
rutile mixtures.
In conclusion, properties and characteristics, such as the ones highlighted here and as well as 
many more, have allowed for the innovative implementation TiO2NMs into drugs, 
treatments, and devices in the field of nanomedicine. Their unique ability to serve as 
vehicles and carriers in PDT have garnered advances in varying cancer treatments and 
improved therapeutic delivery, promoting cellular responses. Additionally, their use in 
cancer therapy is directly resultant of their ability to foster ROS generation. Future advances 
in nanomedicine will more than likely build off the many ways the properties TiO2NMs can 
be exploited.
Gold Nanomaterials
The unique properties of gold-based nanomaterials (AuNMs), such as their optical 
properties biocompatibility, high stability, and multifunctionality, make them highly 
attractive for many applications in nanomedicine.108–110 These applications include, but are 
not limited to, electrochemical sensing, cell and tissue imaging, targeted therapeutic 
delivery, and photo-induced cancer treatments.109–115 Moreover, because of their 
multifunctionality, AuNMs have been used recently as theranostics probes to simultaneously 
target, diagnose, deliver a therapeutic function, and monitor response to therapy in highly 
specific single clinical procedures.110, 111
While gold nanoparticles (AuNPs) generally cannot be considered redox active, the presence 
of AuNPs in biological systems induces other interactions that may cause some biological 
redox responses. AuNPs are an ideal platform for electrochemical biosensors because they 
can act as redox catalysts, enabling enhanced electron transfer for a wide range of 
electroactive biological species (mainly redox proteins) and avoiding the use of electron 
transfer mediators.112, 113, 116–118 Furthermore, their higher surface area provides stable 
immobilization of proteins, retaining their bioactivity and allowing for increased protein 
loading, which provides more sensitivity than flat gold surfaces.113, 116, 119, 120 The main 
research areas for the application of AuNPs in electrochemical sensing involve the direct 
electrochemistry of redox proteins (mainly enzymes), electrochemical genosensors (DNA), 
aptamer sensors and immunosensors for the determination of clinically significant 
biomarkers relevant to the diagnosis and/or monitoring of human diseases (e.g. 
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cancer).117, 121–123 Particularly, AuNPs have been demonstrated to be useful interfaces for 
the electrocatalysis of redox processes with molecules (NADH, cholesterol, glucose, etc.) 
pertinent to many significant biochemical reactions.118, 124, 125 Ciganda et al. demonstrated 
that AuNPs can also act as electron reservoir redox catalysts for 4-nitrophenol reduction (4-
nitophenol is an additive used in manufactured drugs, fungicides, insecticides that causes 
cyanosis, headaches, nausea, etc. in humans), exhibiting a strong stereoelectronic ligand 
influence.126 AuNPs have also been involved in the sensitive detection and quantification of 
ROS such as H2O2 and O2•−.113, 121–123
The role of AuNPs in ROS generation and DNA damage by oxidative stress has been 
significantly studied in recent years. AuNPs induce lipid peroxidation, reduce the levels of 
glutathione peroxidase and significantly increase the levels of 8-hydroxydeoxyguanosine, 
that indicate DNA damage by oxidative stress in rat brain.127 Similarly, AuNPs induce 
oxidative damage through ROS in lung fibroblasts in vitro, which is one source of DNA 
damage.128 Furthermore, in the model organism Drosophila melanogaster, significant 
concentration-dependent and size-independent ROS generation was found, which 
precipitated DNA damage and cell death after ingestion of AuNPs (5 nm to 80 nm size 
range).129 It was also reported that AuNPs may or may not induce oxidative stress in 
different species of marine bivalves.130, 131 Intracellular AuNPs can also promote the 
generation of ROS, leading to ROS-induced DNA damage.132
Nethi et al.133 proposed a novel eco-friendly approach of synthesizing AuNPs by utilizing 
Hamelia patens (HP) leaf extract as a stabilizing/capping agent, which also exhibited an 
excellent pro-angiogenic activity in human umbilical vein endothelial cells. The beneficial 
ability of the bioconjugated AuNPs (HP-AuNPs) to make new blood vessels without 
promoting cancer cell proliferation in vitro, was corroborated in a chicken embryo 
angiogenesis in vivo assay. This finding opens the door to potential applications of HP-
AuNPs in alternative treatment strategies for wound healing and cardiovascular and ischemic 
diseases. On the contrary, in both assays an antiangiogenic activity was observed for PEG-
coated AuNPs (PEG-AuNPs), indicating a crucial role of the coating in the biological 
response. It has been reported that ROS, including H2O2 and O2•−, are established as major 
redox signaling molecules in physiological angiogenesis. Consequently, the detection of 
ROS in endothelial cells after exposure to HP-AuNPs was carried out by fluorescence 
microscopy. The results revealed an enhanced generation of H2O2 and O2•− for cells treated 
with HP-AuNPs compared to PEG-AuNPs, suggesting that the controlled ROS generation 
and consequent redox signaling might be the probable mechanism of HP-AuNPs induced 
angiogenesis. Additionally, HP-AuNPs also enhanced phosphorylation of Protein Kinase B 
(involved in critical signal transduction of various cellular processes) when compared to 
PEG-AuNPs.
Considering the beneficial use of ROS in PDT for cancer, Khaing Oo et al.134 evaluated the 
enhancement of ROS formation by AuNPs. Generally, the AuNP PS conjugates result in 
effective energy or electron transfer between the photoactive dye and AuNP, leading to a 
more effective photodynamic effect. In this case, the size-dependent enhancement of ROS 
formation enabled by AuNPs with different diameters (19 nm, 66 nm, and 106 nm) 
conjugated to a PS, protoporphyrin IX (PpIX), was investigated. They demonstrated that the 
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ROS formation was enhanced proportional to AuNP size after irradiation of PpIX. This 
effect was due to the localized electromagnetic field of the surface plasmon resonance for 
illuminated AuNPs. Concretely, photosensitized 106 nm diameter AuNPs enhanced the ROS 
ratio 5 and 3 times higher than photosensitized 19 nm AuNPs and 66 nm AuNPs, 
respectively. In a subsequent in vitro study, AuNPs were reported to act as cytotoxic agents 
by inducing ROS in the MDA-MB-231 cancer cell line, which lead to significant cell 
destruction.134 The authors also found that the intracellular ROS formation enabled by 
PpIX-AuNP conjugates was also proportional to the size of Au NPs. This ROS enhancement 
greatly depended on the cellular uptake of AuNPs. In fact, when intracellular 1O2 levels 
were monitored as a readout of AuNP uptake, the greatest ROS enhancement was observed 
from 66 nm AuNP-treated cells. Although more than 50 % of breast cancer cell destruction 
was obtained for all PpIX-AuNPs, the 66 nm Au NPs yielded the highest destruction rate 
(60.4 %), consistent with the highest cellular uptake and highest ROS formation. These 
findings clearly shed new light on AuNP-assisted PDT, demonstrating that the size-
dependent ROS generation, cellular uptake, and the complexity of the cellular environment 
all contribute to the overall cellular PDT efficacy.
Di Bucchianico et al.135 investigated the potential in vitro cytotoxicity and genotoxicity 
mechanisms exerted by differently sized AuNPs. The authors used human primary 
lymphocytes and murine macrophages (Raw264.7) that were exposed to different mass 
concentrations and number densities of spherical citrate-coated AuNPs of 5 nm and 15 nm 
diameter. Results indicated that both AuNP sizes significantly decreased the cell viability of 
these two cell models by 20 % to 30 % following exposure to 10 μg mL−1 over 24 h. 
Exposure induced apoptosis, aneuploidogenic effects, and DNA oxidation. Moreover, they 
showed a size-independent correlation between cytotoxicity and their tested mass 
concentration or absolute number. However, it was clearly established that genotoxic effects 
were more severe for larger AuNPs. Overall, they concluded that apoptosis, aneuploidy, and 
both DNA damage and oxidation play a pivotal role in the cytotoxicity and genotoxicity 
elicited by differently sized AuNPs.
Gold nanoclusters (AuNCs) are a particularly interesting subset of gold NMs, with unique 
properties distinct from AuNPs. AuNCs are ultra-small gold particles, with particle 
diameters smaller than 2 nm, which are typically composed of a few to about 100 gold 
atoms. AuNCs exhibit molecule-like properties such as discrete electronic states and size-
dependent fluorescence, and bridge the gap between isolated metal atoms and plasmonic 
metal NPs.136–138. Due to their excellent fluorescence properties, photostability, good 
biocompatibility, and enhanced catalytic activity,139–143 AuNCs have been recently used in 
the field of bioanalysis,142, 144 bioimaging,142, 145 multifunctional control drug 
release,143, 146 theranostics and cancer therapy.143, 144
Unlike AuNPs, AuNCs can be considered redox active NMs because of the quantum size 
effect that leads to discrete electron transition energy levels. For example, hexanethiol-
capped AuNCs (Au147, d = 1.62 nm) display 15 redox states at room temperature,147 
demonstrating that AuNCs can possess molecule-like redox properties.148 These unique 
redox properties can be tuned effectively by external ligands, magnetic fields, electrolyte 
ions, and by controlling the core size.149–153 Moreover, the reversible charge-state 
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conversion of AuNCs indicates that they can be utilized in catalytic oxidation or reduction 
reactions.154 An overview of representative examples of AuNCs as redox catalysts, 
including the reduction of CO2 to CO, the reduction of O2, as well as the oxidation of 
styrene, SO2, cyclohexane, and benzyl alcohol, can be found elsewhere. Although the 
electrochemical properties of the AuNCs have yet to be adequately investigated, an 
electrochemistry approach is well suited to the design and development of commercial 
biosensors. Recently, AuNCs have been reported to act as an electron transfer bridge in the 
electrochemical sensing of different biomolecules such as glucose, ascorbic acid, uric acid, 
dopamine, bilirubin, and H2O2.155–158 A new finding has demonstrated that the strong 
fluorescent signal of AuNCs can be sensitively and selectively quenched by ROS, fostering a 
very promising application field for AuNCs as probes for ROS detection. This new role of 
AuNCs as analytical tools in the oxidative stress field has been recently reviewed.144 An 
illustrative example, based on this approach, is the quantitative determination of H2O2 over a 
wide dynamic range (100 nmol L−1 to 1.0 mmol L−1) with a limit of detection of 30 nmol 
L−1, comparable to other optical H2O2 sensors.159 Furthermore, the use of AuNC-protein 
conjugates to selectively monitor endogenous H2O2 production in live cells by fluorescence 
quenching has been very recently reported.160
Lei et al.161 investigated the capabilities of AuNCs decorated with polypeptide/DNA 
complexes as versatile gene delivery platforms for dual-responsive near-infrared light (NIR) 
and redox activity during gene transfection. Photo-induced endosome/lysosome disruption 
has recently opened a new avenue into the design of gene carriers based on the generation of 
low amounts of ROS after mild light irradiation. Irradiation-induced ROS enables selective 
control over endosome/lysosome escape without destroying the loaded gene and also 
avoiding cell death. AuNCs exhibit superior features versus previous photo-controlled 
delivery systems due to their ROS generation capability, NIR excitation wavelength (808 
nm), greater hydrophilicity, and easier synthesis and modification processes. In this study, a 
polypeptide/DNA complex loaded with the desired gene was decorated with a captopril-
stabilized Au25 nanocluster for its ability to be internalized via endocytosis and generate 
ROS to accelerate endosome/lysosome escape under mild NIR-irradiation. After 
glutathione-induced disulfide bond breakage in the cytoplasm, nuclear translocation results 
in enhanced gene transfection. Followed by glutathione induced disulfide bond breakage in 
the cytoplasm, the nuclear translocation was facilitated resulting in an enhanced gene 
transfection. To avoid the potential cytotoxicity associated with ROS generation by AuNCs, 
AuNC concentrations and NIR light exposure conditions were optimized to guarantee 
biocompability of AuNCs and to prevent cell death. Furthermore, this work successfully 
demonstrated the selective destruction of acidic organelles through NIR irradiation fluence-
modulation. It is expected that this very promising versatile gene delivery platform, based on 
the use of AuNCs as the ROS generator, may be further exploited in new photo-induced 
gene delivery strategies with spatiotemporal control.
In summary, while AuNPs do not impart a direct redox interaction on biologics, AuNCs can 
exhibit molecule-like redox properties. Both gold-based NMs play an important role in the 
electrochemical sensing of redox biomolecules. As described earlier, both AuNPs and 
AuNCs can also participate in the generation of ROS. Overall, their outstanding properties, 
combined with their good biocompatibility and typical low toxicity, make gold-based NMs 
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promising modalities for nanomedical applications. Advances in the use of gold-based NMs 
for nanomedicine applications need to be followed by parallel bio-distribution and toxicity 
studies with maximum care and accuracy to guarantee their success.114, 115, 129, 162–164
Silver Nanoparticles
Recently, silver NPs (AgNPs) have been used for a variety of applications in medicine and in 
commercial products due to their bactericidal properties.165–169 AgNPs have been 
incorporated into bandage formulations to reduce inflammation and promote wound 
healing 170. They are used in a variety of medical procedures and devices to reduce the 
likelihood of infection, such as incorporation into bone cement171 and catheters.172 
Commercially they are used in cosmetics,173 home appliances (e.g., air and water filtration 
systems),174, 175 and textiles.176 AgNPs also have unique plasmonic properties, which have 
been exploited for use in contrast agents for bioimaging, including for photoacoustic 
imaging of cancer cells.177
On a cellular level, AgNPs are internalized through endocytosis pathways and translocated 
to target organelles (e.g., mitochondria, nucleus) where they can activate genotoxic and 
cytotoxic pathways and ultimately lead to cell death.178 The two putative mechanisms by 
which AgNPs contribute to cell death are: 1) through dissolution and subsequent release of 
bioactive silver ions (Ag+)178, 179 and/or 2) through the generation of ROS by either Ag+ or 
AgNPs.167, 178, 180 Several studies have sought to clarify these toxicity mechanisms both 
from the perspective of how they could have potentially harmful effects or how the cell death 
pathways could be used beneficially. For example, research has been conducted from a 
human exposure standpoint by monitoring cytotoxicity to liver cells after their accumulation 
in this organ,181, 182 or by monitoring lung cells in order to understand the potential adverse 
effects of inhalation exposure.183, 184 Other studies have evaluated AgNP cytotoxicity 
mechanisms in fibroblasts and macrophages to understand the use of AgNPs to improve 
wound dressings,185 or in bacteria and cancer cells to understand the role AgNPs could play 
in reducing infection and disease.165–169, 186, 187
Cell viability in the presence of AgNPs is largely dictated by redox mechanisms. 
Translocation of AgNPs to the mitochondria, redox active organelles in the cell, is thought to 
result in the formation of ROS. In many cell lines, ROS cause mitochondrial disruption, 
oxidative stress, DNA damage, and eventual cell death via apoptosis.166, 167, 181–185 This 
redox activity is evidenced in a number of studies; some have shown that low concentrations 
of AgNPs trigger increases in antioxidants like GSH or SOD and decreases in lipid 
peroxidation,181 while others note decreases in antioxidant levels in the presence of AgNPs. 
Specifically, in human liver cells, decreases in GSH were observed along with decreases in 
the protein expression of the catalytically active subunits of two GSH-synthesizing enzymes. 
These responses were accompanied by mitochondrial membrane disruption through down-
regulation of Bcl-2 protein and concomitant up-regulation of Bax protein.182 Bcl-2 prevents 
opening of the mitochondrial membrane, while Bax accelerates its opening. The combined 
effect of their respective down-regulation and up-regulation was shown to induce the release 
of cytochrome C into the cytosol, which triggered the activation of caspase 9 and caspase 3 
leading to cell death via apoptosis.182 Herein, the redox activity of AgNPs is described first 
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in the context of its effects relating to cell death, and subsequently in its utilization as a 
targeted therapy for cancerous cells.
Many of the studies conducted to understand the mechanism through which AgNPs are 
genotoxic or cytotoxic were performed in vitro. To corroborate these studies, work 
conducted in vivo indicates that ROS-dependent pathways play an important role in the 
effects of AgNPs. In one study, Swiss albino mice were analyzed 24 h and 72 h after 
intraperitoneal administration of varying doses of AgNPs (26 mg kg−1, 52 mg kg−1, and 78 
mg kg−1).188 A dose- and time-dependent increase in DNA damage was observed in liver 
cells and lymphocytes. Further, staining of liver tissue samples revealed dose- and time-
dependent apoptosis of liver cells and necrosis in some regions.188 Similarly, other work has 
demonstrated increases in markers of oxidative stress after treating Swiss albino mice with 
varying doses of AgNPs over a period of 14 successive days.189 Depletion of GSH was 
observed in the blood indicating an increase in blood ROS levels, while the effect of AgNPs 
on tissue ROS levels varied depending on location. A significant increase in a DNA damage 
marker was also observed in the urine.189 These in vivo studies have important implications 
for the use of AgNPs for medicinal purposes, and since the most deleterious effects were 
observed for the highest dose of AgNPs administered in each study, these studies highlight 
the importance of dosing in potentially mitigating these adverse effects.
The same mechanisms by which AgNPs may induce harmful effects can be used for the 
development of AgNPs as therapeutic agents. PVP-coated AgNPs have shown increased 
cytotoxic effects against six cell lines from patients with acute myeloid leukemia (AML) 
relative to cells from healthy patients.186 Cytotoxicity was determined to result from the 
generation of ROS, which led to changes in the MMP, DNA damage, and cell death via 
apoptosis. ROS generation was confirmed through a fluorescence assay and through the 
independent introduction of two antioxidants, vitamin C and NAC. Interestingly, both 
vitamin C and NAC attenuated AgNP-induced ROS generation, but only NAC prevented 
losses of MMP, induction of DNA damage, and cellular apoptosis. It was proposed that NAC 
can act as a Ag+ scavenger, which would suggest that losses of MMP, DNA damage, and 
apoptosis are, at least in part, due to the presence of ionic silver.186
In all six AML cell lines, cell viability decreased in a dose-dependent manner for three 
different sizes of AgNPs, with no significant difference in IC50 for AML and healthy cells 
(IC50 ≈ 4 μg mL−1). However, at low AgNP concentrations (≈ 1 μg mL−1 to 2 μg mL−1), cell 
viability decreased more significantly for AML cells than for healthy cells indicating 
increased cytotoxicity of AgNPs to AML cells at low dosage.186 The differential dose-
response at low AgNP concentration is significant when taken together with other research 
exploring the use of biocompatible nanocarriers (NCs) as a means of delivering AgNPs to 
cancer cells with high efficiency and efficacy.187 Specifically, AgNP-chitosan nanocarriers 
(Ag-CS NC) have shown increased cytotoxicity for human colon cancer cells with an IC50 
value of 0.33 μg mL−1. Toxicity proceeds through an apoptotic pathway triggered by 
mitochondrial dysfunction and ROS production. Additional increases in the toxic nature of 
AgNPs towards cancer cells when incorporated into a nanocarrier system coupled with the 
ability of the nanocarrier to be modified for improved biocompatibility and targeted delivery 
potentiates the use of AgNPs as cancer therapies.187
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In summary, AgNPs are promising platforms for the development of novel therapies. In vitro 
and in vivo studies support a mechanism whereby AgNPs induce apoptotic cell death 
through ROS-mediated pathways. While a general understanding of the mechanism of action 
of AgNPs can be extrapolated from the studies described here, it’s important to note that 
cellular response is specific to the AgNP size, surface coating, and concentration, as well as 
the cell line used. Thus, the pathways through which AgNPs may produce impacts are 
highly specific to the system, necessitating additional systematic, well-controlled studies. 
With careful tuning of AgNP properties, their potential for use as direct therapeutic agents or 
as nanocarriers for other small molecules may be realized.
Selenium Nanoparticles
A nonmetal with physicochemical properties between sulfur (S) and tellurium (Te), selenium 
(Se) is present in several proteins that play a critical role in maintaining cellular redox 
homeostasis (glutathione peroxidase, thioredoxin reductase) and thyroid hormone 
production (iodothyronine deiodinase).190, 191 Various inorganic, organic and amino-acid Se 
derivatives have been found to exhibit biological activity, primarily through antioxidant and 
pro-oxidant mechanisms.192–195 Epidemiological studies have identified Se compounds as 
being effective in the prevention and treatment of diseases where oxidative stress is 
implicated, namely cancer, cardiovascular, and neurodegenerative diseases. Due to the 
elevated concentration of both ROS and antioxidants in cancer cells, redox state modulation 
is a possible target for anticancer agents.196, 197 Se has lower electronegativity making its 
compounds more potent reducing agents than S analogues (e.g. ESecysteine = −0.38 V vs 
ECys/Cystine = −0.23 V196). In vivo, Se can be reduced by thiol compounds or oxidized by 
oxygen with both reactions producing ROS that trigger apoptosis. Lung, prostate, cervical, 
and colon cell culture experiments have shown that selenite (SeO32−) acts as a cytotoxic pro-
oxidant in cancer cells.194 However, in vivo studies have also revealed that 
SeO32−administration is toxic if administered at doses outside of the narrow therapeutic 
window.197
The latest research on anticancer properties of Se compounds demonstrated that 
concentration, chemical speciation, redox potential, and treatment model are all critical 
determinants of its therapeutic activity.198, 199 If administered in low doses, inorganic Se 
controls ROS concentration in wildtype cells while in dysplastic cells Se will turn into a pro-
oxidant, which highlights the higher sensitivity of an abnormal cellular phenotype to Se 
supplementation.200,201 In higher doses, SeO32− selectively causes apoptosis in malignant 
cells, while sparing the benign cells.202 Such non-linearity in biological activity led to the 
hypothesis that the Se dose-response curve may have a U shape, which suggests a critical 
role for Se cellular uptake and metabolism control in therapeutic strategies.194, 203 Besides 
direct anti- and pro-oxidant based activities, Se compounds are capable of binding copper 
and iron and thus averting oxidative damage by ROS generated via a Fenton reaction.204 
Evidence also suggests that the increased expression of Se containing thioredoxin protects 
against cardiovascular diseases.205
Recent advances in nanotechnology offer a wide range of novel Se structures with larger 
degree of control over their biological activity and toxicity compared to inorganic and 
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organic compounds.206–210 Control of Se nanoparticle (SeNP) size, shape, morphology, and 
surface structure are the useful properties for tuning their therapeutic efficacy and 
biocompatibility. Elemental Se becomes biologically active when as the red-allotrope 
NP,211–213 which is less toxic than other forms (SeO32−, selenomethionine, 
methylselenocysteine). SeNPs can be prepared by a large variety of physicochemical 
methods (reviewed in214) although so-called green methods are preferred for bio-medical 
applications. Often chemical reduction of SeO32− and/or selenate (SeO42−) by non-protein 
thiols in microorganisms,215, 216 or GSH in the presence of bovine serum albumin produce 
red SeNPs.211 Promising antitumor activity and low toxicity of bare SeNPs to healthy cells 
was achieved for several cancer cell lines.216–220 NP surface functionalization with various 
ligands serves to prevent particle aggregation, modulate cellular uptake and stability, and 
even selectively target cancer cells through binding with overexpressed membrane receptors. 
Se particles with surface ligands containing polysaccharides,221, 222 sialic acid,223 
chitosan,224 folate,225 transferrin,226 undecanol,227 siRNA,228 poly-ethylene-glycol,229 and 
porous silica230 are among recently tested NPs for anticancer application.
A growing trend is to combine Se with other antitumor agents, antibacterial agents, or 
different material-based NPs to generate molecularly-tunable anticancer or antibacterial 
nano-platforms.209, 210, 230–235 Mary et al.229 describe a drug-delivery system designed by 
attaching a crocin, an active product of saffron, to PEG-modified SeNPs. These constructs 
significantly inhibited tumor growth in a nude mice model. At up to 10 % loading, crocin 
inhibited A549 cell growth in a time and dose dependent manner, while showing no effect 
on L-132 cell growth. Moreover, the combination of both crocin and SeNPs was 
demonstrated to have strong synergy in inhibiting cancer cell growth. The authors also 
detected mitochondrial membrane depolarization in treated cancer cells. Depolarization is 
considered to be an initial step in the apoptosis cascade.229 A synergistic effect of the 
anticancer drug doxorubicin with ultra-small SeNPs was also highlighted by Liu et al.230 via 
55 nm porous silica-Se nanospheres impregnated with doxorubicin. Their nano-platform 
showed less than 10 % inhibition of wildtype cell up to 400 μg mL−1, while demonstrating 
cytotoxicity (viability less than 50 %) to HeLa cells in a range from 50 μg mL−1 to 150 μg 
mL−1. In both studies, a pH-sensitive drug release strategy was exploited to discriminate 
between wildtype and cancerous cells. In addition to lower pH, tumor cells also possess a 
higher cytosolic reduction potential;190 this distinction was exploited by Zhang et al.231 who 
developed a “smart nanocarrier” with built-in redox dependent stability. They incorporated a 
diselenide-containing fluorescent molecule with the antitumor drug paclitaxel (PTX) into a 
157 nm diameter particle using a nano-precipitation method. Particle redox sensitivity was 
tested by incubating with GSH, which is the principal cytosolic redox buffer. When exposed 
to GSH, the diselenide bonds were reduced to SeH resulting in time-dependent particle 
disintegration. Cytotoxicity of their NPs against tumor (HeLa and MCF-7) and wildtype 
(BEAS-2B and L929) cells was evaluated using the MTT assay. It was reported that 60 % to 
75 % of cancer cells were killed at 5 μg mL−1 PTX loading compared to 20 % to 25 % of the 
wildtype cells. Combining two or more active compounds in Se containing nano-platforms 
opens new pathways for synergistic treatment of cancer, while also boosting selectivity and 
lowering toxicity to wildtype cells.
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The primary research focus in SeNP biomedical applications is for cancer, yet other ailments 
are also addressed. Kumar et al.236 recently demonstrated that the progression of diabetic 
nephropathy in rats was significantly slowed after administration of SeNPs. Diabetes was 
induced in rats by injecting streptozocin and nephropathy was evaluated by measurements of 
blood nitrogen, creatinine, albumin, fibronectin and collagen. Remarkably, SeNP also 
activated cyto-protective (HSP70) and longevity-related (SIRT1) proteins; oxidative stress 
quenching also modulated apoptotic proteins, Bax and Bcl-2. Towards a potential ALZ 
treatment, Zhang et al.237 designed nano-particles with an anti-amyloid agent, 
Epigallocatechin-3-gallate (EGCG), and selenoproteins to effectively convert protein fibrils 
into non-toxic aggregates. The authors synthesized SeNPs terminated with a neuro-affinity 
peptide, TET-1, to significantly enhance the cellular uptake of the EGCG into PC12 cells. 
Disruption of the interaction between metal ions and peptides is a promising new therapeutic 
strategy for ALZ treatment. Yang et al.238 modified Se/ruthenium (Ru) NPs with L-cysteine 
to create amyloid binding units. These particles were found to suppress a Zn2+-amyloid ROS 
generation mechanism, which resulted in neurotoxicity in PC12 cells. The spherical NPs 
with varying surface charge were shown to significantly decrease the volume of intracellular 
peptide aggregates. The presence of Ru in these NPs also retarded the functioning of random 
coiling, sheet formation and disturbed the alpha helical structures of the amyloids.
In summary, notable advancements in recent years have been made towards developing 
SeNP applications in the biomedical field. Many recent SeNP constructs have been shown to 
possess efficient and selective therapeutic and diagnostic potential. Although some 
mechanistic aspects of Se bioactivity are still unknown, its unique redox properties, versatile 
chemistry and natural biocompatibility are the main drivers for this growing field. Ongoing 
challenges towards the wider acceptance of SeNP-based therapies in clinical practice are 
improving dosing accuracy, potential toxic limits, and better understanding how SeNPs are 
metabolized by the body.
Graphene and its Derivatives
Monolayer graphene is one of the many nanostructured allotropes of carbon (fullerenes, 
CNTs, carbon dots, etc.) that is the subject of extensive research efforts in diverse areas of 
nanomedicine and biology. Initially isolated via the mechanical exfoliation of graphite in 
2004,239 graphene is essentially a 2D monolayer sheet of sp2-hybridized carbon atoms that 
possesses extraordinary chemical and physical properties such as its inherently high 
electrical conductivity. Graphene is especially noted for its remarkable mechanical 
strength,240 superior electronic properties,241, 242 and high thermal conductivity.243 As 
graphene is a monolayer of carbon atoms, all of its atoms are directly on its surface and thus 
graphene has the potential to interact with biomolecules directly. In addition, the surface of 
graphene consists of delocalized π electrons which can be effectively utilized for loading 
aromatic drugs, such as the drugs commonly utilized in cancer chemotherapy. Due to its 2D 
planar nature, graphene is estimated to have the largest specific surface area (≈ 2600 m2 g−1) 
in comparison to most other NMs utilized in biological applications.244 The large specific 
surface area, along with the availability of surface atoms and the presence of delocalized π 
electrons, enables graphene to be an effective nano carrier in which both sides of the 2D 
planar sheet can be functionalized with a variety of drug molecules, targeting ligands and 
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imaging agents. However, the strongly hydrophobic nature of graphene prevents it from 
being widely utilized in nanomedicine applications due its inherent instability and tendency 
to aggregate in aqueous and physiological solutions. Hence most research and applications 
of graphene in nanomedicine focus on the utility of other graphene derivatives such as 
graphene oxide (GO) and reduced graphene oxide (rGO) because these forms have enhanced 
solubility and dispersion properties in aqueous and physiological solutions in comparison to 
graphene.245, 246
Current research on the potential use of GO and rGO and their hybrids and derivatives in 
nanomedicine research is expansive and continuing to grow at a rapid pace. GO and rGO 
find application in 1) drug/gene delivery, 2) phototherapy, 3) biomedical imaging, 4) tissue 
engineering, 5) biosensing and in 6) regenerative medicine.245–256 GO/rGO can function to 
directly oxidize or reduce analytes of clinical or medical importance. The main examples of 
a direct redox functionality for GO/rGO are, of course, the capacity of these materials to act 
as peroxidase-like mimetics257 or as antibacterial/antimicrobial agents.258 Next generation 
graphene derivatives, such as graphene quantum dots (GQDs) have also been shown to be 
unique antibacterial agents. Most recently, GQDs but have been shown to function as direct 
and efficient PSs for use in PDT applications.259
Peroxidases, such as horseradish peroxidase (HRP), are oxidoreductase enzymes that 
scavenge H2O2. HRP works by catalyzing the reduction of H2O2 to H2O by transferring two 
electrons from a substrate that acts as an electron donor.260 A typical substrate, such as 
3,3,5,5-tetramethylbenzidine (TMB), is oxidized and converted into a blue-colored 
compound which can be quantified through spectrophotometric detection. The amount of 
oxidized TMB is directly correlated to the amount of H2O2 present in the system. Recently, 
Song and coworkers257 demonstrated that carboxylated GO (COOH-GO) could function as 
an efficient peroxidase-like mimetic for the quantitative determination of H2O2. The authors 
substituted their synthesized COOH-GO for HRP and showed that the peroxidase substrate, 
TMB, could be efficiently oxidized to a blue compound in solution. In subsequent 
experiments, the authors showed that the peroxidase-mimetic activity of COOH-GO could 
be utilized to determine human blood glucose levels by using the glucose oxidase enzyme to 
convert glucose to H2O2 and then using the COOH-GO/TMB redox reaction to measure the 
generated H2O2. This work illustrates the potential use of COOH-GO peroxidase-like 
catalytic activity for the measurement of glucose levels in diabetic patients. More recent 
studies by Wang and coworkers261 showed that few-layer-graphene (FLG), exfoliated from 
graphite, exhibits peroxidase-like catalytic activity for the detection of H2O2 that is 
approximately 45 times greater than GO and 4 times greater than rGO. This remarkably high 
peroxidase-like activity of FLG was attributed to the higher conductivity in FLG in 
comparison to the conductivity in GO and rGO; FLG was directly exfoliated from graphite 
and it has significantly fewer defect sites than GO and rGO and consequently higher 
conductivity. A complete review of GO and GO-hybrid peroxidase-like mimetics utilized in 
biological applications has been recently published.262
The understanding and characterization of pathogenic bacteria and complex microbial 
communities (microbiomes) is rapidly evolving, yet “superbugs” which demonstrate 
remarkable resistance to common antibiotic treatments threaten to create a global health 
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crisis.263 Novel nanomedicine strategies that are based on the utilization of NMs such as GO 
and GO hybrids to combat multidrug resistant bacteria are gaining traction in this arena.264 
There exists three main mechanisms by which GO has been postulated and sometimes 
demonstrated to effect the destruction of bacteria: 1) direct physical interaction via 
puncturing of the bacterial membrane and subsequent leakage of bacterial contents;265–269 
2) direct physical interaction via wrapping of GO around bacteria leading to nutrient 
deprivation and/or 3) induction of oxidative stress/damage to bacterial membranes via ROS 
generation.267, 270 These putative mechanisms are controversial as some studies show 
supportive data,258, 268 while other studies show conflicting effects or even that GO 
remarkably enhances bacterial growth.264, 271
Currently, the most widely accepted mechanism for the bacteria-killing ability of GO and its 
derivatives is based on their propensity to induce oxidative stress. The pathways by which 
GO can damage bacterial membranes can be either ROS-independent or ROS-
dependent.264, 267, 272 The ROS-independent pathway is exemplified by bacterial 
inactivation without the direct involvement of ROS, but instead, bacterial inactivation 
depends upon the discrete inactivation of intracellular biomolecules that are critical for 
bacterial survival.267, 273 For example, Liu and coworkers267 showed that four different 
types of graphene-based materials (graphite, graphite oxide, GO and rGO) were all able to 
inactivate E. coli to varying degrees due to a combination of membrane damage and 
oxidative stress damage. However, none of the materials produced detectable acellular ROS 
levels in the form of O2•− (as measured by an XTT assay), but all the materials could oxidize 
acellular GSH to glutathione disulfide (GSSG). Interestingly, the rGO material induced the 
greatest oxidation of GSH, but GO had the strongest effects on E. coli inactivation. The 
authors hypothesized that since rGO is a much better electrical conductor than the other 
graphene materials utilized in the study, it was better able to mediate electron transfer from 
GSH to the external environment. GO, on the other hand, had the advantage of small size 
and better dispersibility and was thus able to encounter the bacteria and induce membrane 
stress.
ROS-dependent pathways for bacterial inactivation by GO and its derivatives are based upon 
having a proportionally high density of defect sites on the basal planes and edges of GO. 
Several investigators have postulated that molecular O2 adsorbs to these defect sites and 
undergoes reduction (mediated by electron transfer) in the presence of antioxidant small 
molecules and enzymes to ROS.274, 275 These ROS can undergo subsequent release into the 
immediate environment and inactivate bacteria. Recent reports illustrate the feasibility and 
practicality of utilizing GO and GO-hybrids to inactivate a variety of Gram-positive and 
Gram-negative bacteria. Gurunathan and coworkers276 applied the nitro blue tetrazolium 
(NBT) reduction assay to show that both GO and rGO efficiently produce ROS (O2•−) that 
effectively contribute to the decreased cellular viability of Pseudomonas aeruginosa. Kim 
and coworkers also demonstrated that O2•− (detected via an XTT assay) generated from a 
GO-hydride nanocomposite film, GO-MoS2, could inactivate E. coli K-12 (DH5a) cells. In 
another example illustrating the use of a nanohybrid, Nanda and coworkers277 prepared a 
GO-cystamine drug delivery agent and confirmed its effectiveness in mediating the 
generation of ROS against E. coli and three other pathogenic bacteria. GQDs are unique 
antibacterial materials which share characteristics of both graphene and carbon dots; GQDs 
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are inherently biocompatible and demonstrate peroxidase-like activity. Sun and 
coworkers278 showed that GQDs can, in the presence of low levels of H2O2 (1 mmol L−1 to 
10 mmol L−1), catalyze the formation of •OH. The authors demonstrated the effectiveness of 
the generated •OH to inactivate both E. coli and S. aureus bacteria, to inhibit biofilm 
formation and to help heal wounds in mice.
The potential clinical utility of GO antibacterial oxidative coatings for medical devices was 
recently described by Li and coworkers.258 In their research, the authors used chemical 
reduction and hydration procedures to specifically prepare a library of GO materials with 
known levels of oxidized functional groups and carbon radicals (•C) on their surfaces. The 
GO library was tested on antibiotic resistant Gram negative (E. coli) and Gram-positive (L. 
crispatus) bacteria and the authors noted that the highest bacterial killing was strongly 
correlated to the GO material with the highest level of hydration (hGO-2) and with the 
highest level of •C radicals on the surface. The •C radical is formed on GO surfaces during 
the hydration process as epoxy rings open. The mechanism for the antibacterial effects of the 
•C radical is based on the presence of unpaired electrons that endow it with a large pro-
oxidative potential. The •C radical oxidizes membrane lipids to initiate lipid peroxidation 
reactions (confirmed by flow cytometry experiments on the bacterial cells) that are lethal to 
the bacteria. The authors further demonstrated the antibacterial effects of the •C radical by 
preparing films of hGO-2 on glass substrates and also covalently bonding hGO-2 to the 
surface of silicone catheters. In both hGO-2 cases, antibiotic resistant E. coli suffered 
increasing levels of membrane damage and fragmentation.
GO and its derivatives have been increasingly investigated as nanocarriers and/or as drug 
delivery vehicles for the treatment of different types of cancers. GO, because of its flat sp2-
hybridized carbon network can adsorb hydrophobic molecules via π-π stacking and 
transport these molecules into cells and organs with high efficiencies. In particular, GO has 
been explored as a carrier for transporting nontoxic dye PSs (the source of the 1O2) into 
tumors as part of anticancer PDT. The theoretical and experimental utility of GO and its 
relevant derivatives in PDT has been thoroughly reviewed.279, 280 Next generation graphene-
based PDT agents are based on GQDs281–283 which have been demonstrated to be 
biocompatible, to not suffer from photobleaching, and to have extremely large 1O2 quantum 
yields following visible light irradiation. When utilizing GQDs, the GQD is the actual PDT 
agent directly producing 1O2; the GQD is not a nanocarrier for a PS. In fact, Ge and 
coworkers281 recently synthesized a water dispersible GQD based on the use of a 
hydrothermal synthetic route that produced the highest 1O2 quantum yield (≈ 1.3) of all 
currently utilized PDT agents (about twice as high as the best PDT agents). The authors 
described the successful use of the GQDs in both in vitro and in vivo exposure scenarios. 
Following visible light irradiation (405 nm and 633 nm lasers) in the presence of HeLa cells, 
GQDs induced dose dependent decreases in cellular viability and cell shrinkage. Direct 
injection of the GQDs into MDA MB-231 tumor-bearing mice in combination with PDT 
resulted in permanent tumor shrinkage and destruction after 17 d and no tumor regrowth 
after 50 d in comparison to control mice. It is possible that these emerging PDT agents may 
also be applicable for combating drug-resistant microorganisms.
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The prospects for the further development of graphene-based materials for nanomedicine 
applications are highly promising, yet concerns regarding the potential long-term toxicity of 
graphene remain. Current graphene researchers have explicitly expressed the need for 
methods and data that can be utilized to better characterize the in vivo pharmacokinetics and 
toxicological profiles of graphene materials used for nanomedicinal therapy.245 The main 
problem is that graphene-based materials, and specifically GO, are not rapidly eliminated 
from the body, but instead, are passively retained in the reticuloendothelial system (RES) 
organs. The kidney is not able to effectively clear NMs larger than about 5 nm,284 thus GO 
has to enter the liver and become part of the bile and feces in order to be eliminated. This is 
a very slow process that can potentially contribute to the long-term toxicity of GO and other 
graphene-based materials. However, it was recently hypothesized that GO may not be as bio-
persistent as expected. Kotchey and coworkers285, 286 demonstrated that GO, as well as other 
carbon NMs containing carboxylated functional groups can be rapidly oxidized and 
degraded over time in the presence of HRP enzyme and H2O2. Thus, it is feasible that 
human-based peroxidases, such as myeloperoxidase, eosinophil peroxidase, and 
lactoperoxidase may actively contribute to the enzymatic biodegradation of GO and its 
derivatives in vivo. Additional studies on the endogenous biodegradation of GO by human 
peroxidases is warranted.
Higher Order Carbon Nanomaterials
The initial use of higher-order carbon nanomaterial (CNM) allotropes (fullerenes: Bucky 
balls, carbon nanotubes (CNTs), carbon quantum dots (CQDs), etc.) in living cellular 
systems was driven by proposed studies of their basic transport properties and bio-molecular 
interactions, as well as their cell scaffolding, photonic, membrane sorption, and delivery 
applications.287–295 Reports of their unique chemical, structural (size/shape), optical, and 
electronic (also electrochemical) properties predate their biological use.296–302 Importantly, 
the scale of many CNMs is on the same order of magnitude as many biological materials.
The chemical and interfacial properties of carbon fullerenes impart a rich platform for bio-
reactive and supramolecular chemistry applications. In regard to their physical properties, 
carbon fullerenes have large surface areas made of carbon atoms arranged depending on the 
allotrope in question:303 CNTs are tube-like hollow fullerenes made of hexagonal lattice 
repeats of sp2 hybridized π systems. Their surfaces are graphene-like, rigid, curved, and free 
of lattice distortions (Figure 1a). The CNTs comprise multi-walled (MWCNT), single-
walled (SWCNT), and double-walled (DWCNT) varieties. Diameters range from sub-1 nm 
to 3 nm for SWCNTs, and can range from 5 nm to 30 nm for MWCNTs. CNTs possess a 
uniquely large aspect ratio that can surpass a factor of 1000. Stable and individualized CNTs 
have been prepared at length scales that range from ultra-short 10 nm to μm long. The 
spherical (Bucky) fullerenes (prototyped by the hexagonal/pentagonal C60) shown in Figure 
1b are reported to range in diameter from 0.4 nm to 1.6 nm,304 and the amorphous-to-
crystalline CQDs (discovered during SWCNT purification305) depicted in Figure 1c have 
curved surfaces below 10 nm in diameter.306–308 Additionally, the single-walled carbon 
nanohorns (SWCNH, Figure 1d) have interesting cone-like shapes with diameters ≈ 2 to 5 
nm that can aggregate into stable star-shaped structures.309 Lastly, the amorphous carbons 
(Figure 1e) such as carbon black (e.g. charcoal) and hydrophilic carbon clusters (HCC) are 
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comprised of distorted carbon lattices that routinely incorporate heteroatom dopants, like 
oxygen. A notable property of higher-order CNMs is their biological stability—with the 
possible exception of peroxidase systems in particular immune cells,310, 311 the lattices of 
these NMs are resistant to biochemical corrosion.
A common surface property that all CNMs share is hydrophobicity, or a lack of water 
wettability.312–314 Hydrophobic effects and van der Waals (Keesom, Debye, and London) 
forces determine surface and electronic interactions. Therefore, functionality is critical when 
investigating potential biological redox interactions because, (1) CNMs must be 
functionalized to become soluble for biological use, and (2) local environmental and 
interface properties impact reaction kinetics.315 Functionalization of CNMs is generally 
classified into covalent and non-covalent modification.316 Common non-covalent 
functionalities include amphiphilic (hydrophobic and hydrophilic) polymers, molecules, and 
bio-polyelectrolytes such as DNA and carboxymethyl-cellulose. Covalent modifications 
include direct functionalization of the carbon lattice to attach acids, bases, and other tailored 
chemistries.
The electrochemistry of higher-order CNMs largely depends on the electronic band structure
—metallic, semiconductor, or insulator—of the CNM. The amorphous/glassy 
nanocarbons,317, 318 CNTs,319–323 and Bucky fullerenes324 have been characterized in 
detail. In open-circuit aqueous systems such as biological media/serum, the O2/H2O redox 
couple dominates (e.g. see325–329) and must be factored into the presence of other interfering 
redox couples that are not NM targets. Notable interactions and applications of these carbon 
allotropes are described below.
In semiconducting Bucky fullerenes (Figure 1b), energy input in the form of visible light is a 
popular means to promote free radical reactions and charge-transfer complexes. 3O2 will 
interact with excited fullerenes to generate 1O2 or O2•−. This is possible because these 
fullerenes are stable in various reversible anionic states and have favorable singlet-triplet 
conversions and lifetimes.324 Lu et al.330 employed the fullerene C60 in a PDT approach to 
kill Gram-negative bacteria found in wound infections (P. aeruginosa and P. mirabilis), 
which is a critical issue that can lead to systemic sepsis in emergencies. In contrast, Gram-
positive strains tend not to produce sepsis and are readily sensitive to PDT. Previous work 
found that quaternary pyrrolidinium (cationic) functionalization of C60 (BF6) increases the 
killing of Gram-positive bacteria, Gram-negative bacteria, and fungal yeast.331 Such 
fullerenes are thought to act via photo-activated mechanisms that involve O2•− and •OH. In 
vitro culture experiments used a non-coherent lamp with 400 nm to 700 nm white-light 
band-pass filters to test the visible spectrum. An illumination time of 50 s (10 J/cm2) was 
used to show the dose-dependent killing ability of photoactive BF6. For in vivo experiments, 
2.5 × 107 log-phase bacterial cells were placed onto an excisional wound on the back of 
BALB/c mice susceptible to terminal septicemia. In the dark, the 15 min BF6-exposed 
wound produced a minimal reduction, but no trend, in the bioluminescence used to track live 
P. mirabilis bacteria. Survival in these mice was 16 %. White-light illumination of the mice 
showed a dose-dependent reduction in bioluminescence which translated to a survival of 
82 % after 15 d. In contrast, infection of mouse wounds by P. aeruginosa behaved 
differently. BF6 treatment and illumination resulted in a 95 % reduction of bioluminescence; 
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however, 100 % of mice died from sepsis within 3 d. The authors discovered that the P. 
aeruginosa had recovered after 24 h and had infected surrounding tissue. The authors 
decided to combine the BF6 with a modest antibiotic regimen (6 mg kg−1 Tobramycin for 1 
d). The antibiotic alone showed no efficacy, but increased rodent survival to 20 %. When the 
antibiotic was combined with BF6, the authors found the same dose-dependent reduction in 
bioluminescence seen with illuminated BF6 alone. However, upon examination after 24 h, 
there was no bacterial regrowth and no invasion into surrounding tissues. Mouse survival 
increased to 60 % after 15 d. The authors concluded this study to be the first experimental 
evidence of a fullerene-mediated curative treatment for a fatal disease in rodents. The 
authors mention the unusual photochemical mechanism (Type I) was quite effective versus 
the common Type II mechanism shown in analogous studies. Surprisingly, the authors found 
that a sub-clinical dose of antibiotic (Tobramycin) therapy could prevent the re-growth of the 
aggressive strain after BF6 illumination.
Amorphous and glassy carbons (Figure 1e) are generally of metallic or insulating character, 
depending on their surface features and lattice. The insulating materials are notable for their 
double-layer capacitive currents and are therefore inert in open-circuit. However, depending 
on their surface chemistry, reduction-oxidation may occur in highly acidic/alkaline media. A 
complex oxygen-reduction reaction (ORR), similar to the end product of the mitochondrial 
respiratory chain, can occur in media pH>7.0.332 For perspective, this general mechanism 
underlies iron-mediated cancer cell death induced by another class of insulator-like NPs.333 
Huq et al.334 utilized bio-compatible PEGylated hydrophilic carbon clusters (HCCs) to 
scavenge O2•−, and •OH. These particles were studied previously for nano-vectors335 and for 
their antioxidant action in traumatic brain injury (TBI) models.336 In rodents, these HCCs 
accumulate in the spleen, a secondary lymphoid organ, in contrast to canonical NM 
phagocyte uptake after systemic injection. Maximum blood circulation of HCC was reached 
24 h after injection. Versus a carbon black (India ink) control, the authors find their HCCs 
take a similar lymphatic route but are not internalized by node or thymus macrophages and 
T lymphocytes. Rather, splenic T-cell uptake selectivity was confirmed ex vivo. 
Interestingly, HCCs are continuously exocytosed/recycled after internalization rather than 
degraded in the endolysosome. In culture, HCCs reduce intracellular O2•− levels and 
therefore the proliferation of antigen-stimulated, myelin protein-specific primary rat CD4+ 
T-cells. The reduction in intracellular O2•− requires HCC internalization and effects 
proliferation indirectly through radical scavenging. Compared to the HCCs, vitamin C and 
water-soluble vitamin E have no effect on T-cell proliferation. Assay showed that the HCCs 
exert a selective effect on inflammatory signaling molecules such as IL-2 and INF-γ, but not 
IL-17A, indicating the anti-oxidant mechanism modulates a distinct signaling pathway. An 
in vivo model of delayed-type hypersensitivity (DHT type IV), which displays memory T-
cell-mediated inflammation, was abrogated after a single subcutaneous dose (2 mg/kg) of 
HCC at the time of immunization or subsequent challenge. A similar result was found after 
injection of ovalbumin-specific T-cells followed by challenge. The injected T-cells had no 
homing defect at the inflammation site, indicating the HCCs behave similarly to T-cell 
immunomodulator drugs on the market. A subsequent test of HCCs in rats with acute 
autoimmune encephalomyelitis (EAE, a MS model) indicated that subcutaneous HCC 
treatment every three days after the onset of clinical signs can reduce disease severity 
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(clinical behavioral score) and inflammatory foci in spinal cord grey matter. Intracellular 
O2•− scavenging to modulate T-cell activity, as well as prevent immune cell infiltration into 
the central nervous system in the EAE model, are interesting and unique applications of 
these insulator-type carbon clusters.
The CNT properties vary depending on their type (SWCNT, DWCNT, and MWCNT, Figure 
1a) since only the limiting (outer) surface is electrochemically active.337 The metallic 
(mCNT) or semiconducting (sCNT) band structure dictates reactivity; mCNT are inherently 
more electroactive in open-circuit when compared to sCNT. The mCNTs are quantum wires 
that undergo rapid charge accumulation in solution via surface functionalization, adsorption, 
and/or condensation interactions.325, 338, 339 Compared to Bucky fullerenes, the SWCNT 
lattice is rather un-stable in an anionic/cationic state (the DW/MWCNT are more 
stable).340, 341 This instability suggests that a redox path might be from a biological 
reductant, NADH, to CNT or CNT-associated functionality (or both), then into water, 
oxygen, or other relatively oxidizing agents.342, 343 This should result in no net charge 
generated on the CNT lattice. The CNT surface functionality (covalent or non-covalent) is 
thought to be important in this relaxation/transfer process. sCNTs are capacitive 
materials319, 320, 344 that seem to promote electronic relaxation of redox species with oxygen 
in quasi-dark open-circuit conditions.342, 343, 345, 346 For example, ad-atom cations may 
mediate this activity.326, 343 Notwithstanding, a precise path of the transfer is unknown. A 
similar relaxation mechanism through large bandgap (small diameter) sCNTs may underlie 
their anti-oxidant protective actions on biopolymers in the presence of dangerous •OH and 
possibly solvated electrons (e•).347 Otherwise, condensed transition metals like gold (AuCl3) 
and iridium (K2IrCl6) are necessary to transform the sCNT into a canonical electroactive 
material339, 348 analogous to platinum electrodes and TiO2 NPs. Under conditions that favor 
stable van der Waals interaction with the sCNT, photon energy permits long-lived radical ion 
pairs with photoactive bioinorganic dyes.349 sCNT surface delocalized photoexcitations can 
form ionized carriers whose formation is controlled by extrinsic factors such as excitation 
fluence, permittivity, surface electrostatics, and chemical environment.295, 350–358 For these 
reasons, bio-toxic proteins can be deactivated after high fluence illumination of sCNT 
produces O2•− and/or amino acid radicals.359
While the photochemical nature of the sCNTs is not fully understood in biological 
environments, covalent modification of CNTs is used as a means to manipulate ROS 
generation. For example, based upon prior evidence that a) –OH and –COOH functionalized 
CNTs can chelate metals, b) suggestions that CNTs possess antioxidant capability 
against •OH, c) some evidence that covalently functionalized CNTs have a greater organic 
partition coefficient (logP), and (d) observations that π-π interactions between CNTs and 
biological electron transport proteins can modulate underlying transport dynamics, 
Gonzalez-Durruthy et al.360 tested a battery of CNTs in ex vivo mitochondrial preparations 
for H2O2 production (Amplex Red assay) after iron overload. Iron is the most abundant 
transition metal in the human body and mitochondria can rapidly accumulate Ca2+ and Fe2+ 
in pathological situations; the indiscriminate and aggressive nature of •OH radicals produced 
through Fe2+ interaction with H2O2 after electron transport chain leak promotes cellular 
death and disease. The authors tested whether CNTs could modulate this oxidative 
mechanism. Safranine O was used to confirm the CNTs do not damage mitochondrial 
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membrane functionality in fractionated preparations. The author’s panel of CNTs possessed 
chemical functionalization-dependent effectiveness against H2O2 production by 
mitochondrial preps from tissues. The authors used cyclic voltammetry (CV) to corroborate 
the ability of various CNTs to prevent •OH formation from iron-EDTA/H2O2 Fenton-Haber-
Weiss reactions. Importantly, CV was conducted within an electrochemical potential 
window corresponding to the potential drop across the mitochondrial redox chain. A 
fluorometric assay of Fe2+ chelation efficiency versus EDTA indicated the mechanism is 
partially due to the iron-chelating ability of the –COOH functionalized CNTs and possibly 
the surface π system. CNTs incubated with mitochondrial preps showed no adverse effects 
on native mitochondrial ion transport systems, further suggesting to the authors that CNTs 
indirectly impact the ROS producing components of the electron transport chain. In what 
might be considered a novel melding of application and theory, the authors utilized a QSPR/
QSAR chemoinformatics approach to test the prediction that •OH scavenging by CNMs is 
dependent on functionalization. While this study integrated many disparate concepts, its 
ability to piece out a possible mechanism through which CNTs synergize with the electron 
transport chain of the mitochondrion is interesting. It should be noted that a similar concept 
is thought to operate when non-covalently modified sCNT are delivered into plant 
chloroplasts for the purpose of augmenting phototransduction.361
The quantum-like carbon dots (Figure 1c) show promise given their highly tunable 
semiconductor bandgap. A favorable bandgap permits visible light excitation and photo-
activation for applications in photobiology and phototherapy, reviewed elsewhere.362, 363 
Lastly, recent carbon nanohorn (CNH, Figure 1d) studies highlight the counterintuitive 
nature of higher-order carbon nanomaterial effects in biology. No distinct changes in 
intracellular ROS levels or cellular proliferation have been noted after treatment with broad-
range concentrations of as-produced or albumin-dispersed CNH,364, 365 even though these 
allotropes have semiconductor properties. Interestingly, CNH photosensitization becomes 
apparent when CNH are pre-oxidized, loaded with photoactive dyes, albumin dispersed, and 
illuminated.366 CNHs highlight a key relationship between CNM structure (chemical, 
electrical, and surface) and function in biological environments.
To conclude, current work on higher-order CNMs in biology has been directed towards 
several goals: (1) the determination of upstream cellular pathways that detect/diagnose the 
presence and/or reactivity of CNMs. This remains an active area of nanotoxicology. (2) The 
standardization and evaluation of material preparation procedures to address material 
artifacts and reproducibility.367, 368 (3) Particular challenges related to bio-redox assay 
cross-interactions with the NM itself.369 (4) Research that seeks to impart selectivity and in 
some cases specificity to NM reactivity in biological systems through functionalization and 
surface science. The applications reviewed above highlight the potential promise of CNMs 
in redox targeted medicine and in basic studies of bio-nano interactions.
Future Perspectives
Within the framework of the previously described nanomedicine modalities, a common 
thread which connects them all together is the ongoing concern related to their potential 
adverse effects on human health and safety. The understanding, characterization and 
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evaluation of the potential acute and/or chronic toxicological properties of NMs is as 
important to nanomedicine applications in the healthcare industry, as it is for the consumer 
products, agriculture and electronics industries.370–372 While it is certainly true that no 
commercial non-nano based medicine is absolutely free of toxicity or potential adverse 
effects,373 it is practical and worthwhile from both a safety and ethical point-of-view to try 
to design out toxicity in nanomedicines or to develop safer-by-design nanomedicines where 
functionality is optimized and toxicity is minimized. In cases where the nanomedicine 
functionality is based on redox-activity, completely designing out biological reactivity may 
be illogical, but what would be logical is to have a more complete understanding of how the 
base NM induces off-target effects on the immune system, nervous system, macrophages, 
etc. To achieve this outcome, we will need to move away from a focus on descriptive 
toxicology to an emphasis on predictive toxicology. There are simply too many different 
types and formulations of NMs, such that it is not practical to evaluate on a case-by-case 
basis an exponentially growing number of NMs utilized in the potential formulation of 
nanomedicines or medical materials. Alternative testing strategies that use predictive 
toxicology models and high content screening of cellular models to predict NM toxicity to 
humans may be a viable option, which warrants serious consideration.374–377
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Ag-CS NC AgNP-chitosan nanocarriers
AgNPs silver nanoparticles
AML acute myeloid leukemia
ALZ Alzheimer’s disease
AuNCs gold nanoclusters
AuNPs gold nanoparticles
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BF6 quaternary pyrrolidinium (cationic) functionalization of 
C60
β-lap β-lapachone
CMP cell membrane potential
CNMs carbon nanomaterials
CNPs cerium oxide nanoparticles
CNTs carbon nanotubes
COOH-GO carboxylated graphene oxide
CQDs carbon quantum dots
CV cyclic voltammetry
DHT type IV delayed-type hypersensitivity
DNA deoxyribonucleic acid
DWCNTs double-walled carbon nanotubes
EAE acute autoimmune encephalomyelitis
EDTA ethylenediaminetetraacetic acid
EGCG epigallocatechin-3-gallate
ESR electron spin resonance
Fe3O4 magnetite
γ-Fe2O3 maghemite
FLG few-layer-graphene
G graphene
GO graphene oxide
rGO reduced graphene oxide
GQDs graphene quantum dots
GSH glutathione
GSSG glutathione disulfide
H2O2 hydrogen peroxide
HCCs hydrophilic carbon clusters
HNE 4-hydroxy-2-nonenal
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HP Hamelia patens leaf extract
HRP horseradish peroxidase
IONs iron oxide nanoparticles
JNK c-Jun N-terminal kinase
MIRB Molday ION Rhodamine B
MMP mitochondrial membrane potential
MRI magnetic resonance imaging
MS multiple sclerosis
MWCNTs multi-walled carbon nanotubes
NAC N-acetyl cysteine
NIR near-infrared
NMs nanomaterials
NPs nanoparticles
NSCs neural stem cells
•OH hydroxyl radical
•OOH hydroperoxyl radical
O2•− superoxide anion radical
ORR oxygen-reduction reaction
PARP1 poly(ADP-ribose) polymerase 1
PDT photodynamic therapy
PEG polyethylene glycol
PEG-b-PDPA poly(ethyleneglycol)-b-polu(2-(2-diisopropylamino) ethyl 
methacrylate
PpIX protoporphyrin IX
PSs photosensitizers
PS* singlet excited state photosensitizers
PS** triplet excited state photosensitizers
PTX paclitaxel
PVP polyvinylpyrrolidone
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ROS reactive oxygen species
sCNTs semiconducting carbon nanotubes
SeNP selenium nanoparticles
SMA smooth muscle actin
SOD superoxide dismutase
SPIONs superparamagnetic iron oxide nanoparticles
SWCNHs single-walled carbon nanohorns
SWCNTs single-walled carbon nanotubes
TiO2NMs titanium dioxide nanomaterials
TiO2NPs titanium dioxide nanoparticles
TMB 3,3,5,5-tetramethylbenzidine
UV ultraviolet
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Figure 1. 
(a) A carbon nanotube. The d2 diameter indicates a single-walled material, whereas d1 
indicates the total diameter of a double-walled material. Multi-walled CNTs consist of 
additional lattice layers, (b) A carbon Bucky Fullerene with diameter d. (c) A carbon 
quantum dot with diameter d. (d) A single-walled carbon nanohorn segment of diameter d 
which tapers at an angle towards its tip. The arrow points towards the aggregate star 
structure. (e) An amorphous carbon particle with hydrophilic oxygen functionalities 
(hydroxyl: OH, carboxylic: COOH).
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